WASHINGTON -- Freedom from relapse was maintained in multiple sclerosis patients on natalizumab (Tysabri) who received the infusion drug less frequently than the recommended 4-week interval, with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback